A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ASSESS SINGLE DOSE AND MULTIPLE DOSE PHARMACOKINETICS OF PF-04965842 AND ITS METABOLITES, AND THE EFFECT OF REPEAT-DOSE PROBENECID ON THE SINGLE DOSE PHARMACOKINETICS OF PF-04965842 AND ITS METABOLITES IN HEALTHY PARTICIPANTS
Latest Information Update: 07 Mar 2022
At a glance
- Drugs Abrocitinib (Primary) ; Probenecid
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 28 Feb 2022 Results of a pooled analysis (NCT03634345, NCT03637790 and NCT03937258 studies) assessed the effects of CYP inhibition, CYP induction, and OAT3 inhibition on the pharmacokinetics of abrocitinib, its metabolites, and active moiety published in the European Journal of Drug Metabolism and Pharmacokinetics
- 23 Aug 2019 Status changed from recruiting to completed.
- 30 May 2019 Status changed from not yet recruiting to recruiting.